North China Pharmaceutical Co Ltd (600812) — Cash Flow Quality Index
North China Pharmaceutical Co Ltd (600812) has a Cash Flow Quality Index of 4.86x as of September 2025. Operating cash flow of CN¥170.24 Million exceeds net income of CN¥35.01 Million, indicating high earnings quality where cash backs reported profits. Explore North China Pharmaceutical Co Ltd operating cash flow efficiency to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
North China Pharmaceutical Co Ltd Cash Flow Quality Index (1998–2025)
Historical Cash Flow Quality Index for North China Pharmaceutical Co Ltd across 25 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check North China Pharmaceutical Co Ltd (600812) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for North China Pharmaceutical Co Ltd (1998–2025)
Year-by-year earnings quality comparison for North China Pharmaceutical Co Ltd. For live market cap and the full company financial profile, see market value of North China Pharmaceutical Co Ltd.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 6.43x | CN¥1.18 Billion | CN¥183.06 Million | ▲ +12.4% |
| 2024 | 5.72x | CN¥1.23 Billion | CN¥214.97 Million | ▼ -97.3% |
| 2023 | 209.45x | CN¥1.02 Billion | CN¥4.89 Million | ▲ +605.6% |
| 2021 | 29.68x | CN¥1.05 Billion | CN¥35.38 Million | ▲ +312.3% |
| 2020 | 7.20x | CN¥752.15 Million | CN¥104.48 Million | ▲ +45.3% |
| 2019 | 4.96x | CN¥732.97 Million | CN¥147.90 Million | ▼ -6.7% |
| 2018 | 5.31x | CN¥774.33 Million | CN¥145.82 Million | ▼ -73.3% |
| 2017 | 19.90x | CN¥287.25 Million | CN¥14.44 Million | ▲ +330.0% |
| 2016 | -8.65x | CN¥-446.53 Million | CN¥51.63 Million | ▼ -459.0% |
| 2015 | 2.41x | CN¥122.50 Million | CN¥50.85 Million | ▼ -15.4% |
| 2014 | 2.85x | CN¥90.56 Million | CN¥31.79 Million | ▲ +120.0% |
| 2013 | -14.22x | CN¥-135.03 Million | CN¥9.49 Million | ▼ -212.9% |
| 2012 | -4.55x | CN¥-63.92 Million | CN¥14.06 Million | ▼ -379.5% |
| 2011 | 1.63x | CN¥227.60 Million | CN¥139.96 Million | ▲ +171.2% |
| 2010 | -2.29x | CN¥-598.35 Million | CN¥261.81 Million | ▼ -157.7% |
| 2008 | 3.96x | CN¥1.09 Billion | CN¥273.95 Million | ▼ -55.8% |
| 2007 | 8.96x | CN¥664.37 Million | CN¥74.11 Million | ▼ -14.2% |
| 2006 | 10.45x | CN¥597.12 Million | CN¥57.12 Million | ▲ +145.2% |
| 2004 | 4.26x | CN¥310.39 Million | CN¥72.81 Million | ▲ +104.1% |
| 2003 | 2.09x | CN¥580.32 Million | CN¥277.87 Million | ▼ -48.4% |
| 2002 | 4.05x | CN¥738.50 Million | CN¥182.52 Million | ▲ +116.9% |
| 2001 | 1.87x | CN¥367.28 Million | CN¥196.84 Million | ▲ +89.0% |
| 2000 | 0.99x | CN¥133.49 Million | CN¥135.24 Million | ▲ +131.8% |
| 1999 | -3.10x | CN¥-373.62 Million | CN¥120.50 Million | ▼ -13.8% |
| 1998 | -2.73x | CN¥-326.74 Million | CN¥119.90 Million | — |